医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Santen Pharmaceutical to Leverage Medidata Edge CTMS to Drive Future Growth in Ophthalmic Clinical Development

2018年02月20日 PM10:30
このエントリーをはてなブックマークに追加


 

NEW YORK

Santen Pharmaceutical Co., Ltd, is expanding its use of the Medidata Clinical Cloud® with the adoption of Edge CTMS (Clinical Trial Management System) to support its clinical trial operations, in ophthalmology, across Japan, Asia, USA and the EU. Santen becomes the first sponsor to adopt Medidata Edge CTMS in the Japanese market.

Medidata is the leading global provider of cloud-based technology and data analytics for clinical research. As Santen strives to globalize its research and development operations, the company will deploy Edge CTMS to streamline trial activities, increase productivity and improve efficiency of trial execution.

Edge CTMS provides real-time visibility into clinical trial milestones, allowing Santen to evaluate operational effectiveness and implement changes rapidly. It also seamlessly integrates with Rave EDC, the industry-leading EDC solution, enabling Santen to dramatically speed trial execution by managing both study and trial data on a single unified platform.

“There is a growing demand to simplify, improve efficiency and create transparency across clinical trials. The Medidata Edge CTMS solution makes it possible for life science companies to achieve all three on our unified platform,” said Glen de Vries, Medidata president and co-founder. “We look forward to strengthening our relationship with Santen, and helping to streamline workflows across their R&D, globally.”

About Santen

As a specialized company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).

About Medidata

Medidata’s unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220005876/en/

CONTACT

Medidata Solutions
Investors:
Betsy
Frank, +1 917-522-4620
bfrank@mdsol.com
or
Media:
Erik
Snider, +1 646-362-2997
esnider@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SpinalCyte、CybroCell™注入後のMRI評価が12カ月間にわたり維持されたと発表
  • SpinalCyte宣布,注射CybroCell™后,MRI转归可维持12个月
  • 術後貧血管理に関する国際的合意声明でMasimo SpHb®を含む非侵襲的ヘモグロビン測定が推奨される
  • 关于术后贫血处治的国际共识声明推荐包括Masimo SpHb®在内的血红蛋白无创测量
  • Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein